Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 102-107

  Beyazit, Yavuz ^a   Koklu, Seyfettin ^b   Tas, Adnan ^b   Purnak, Tugrul ^b   Sayilir, Abdurrahim ^a   Kurt, Mevlut ^a   Turhan, Turan ^b   Celik, Tugrul ^b   Suvak, Burak ^a   Torun, Serkan ^a   Akbal, Erdem ^b  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Adenosine deaminase; Disease activity; Ulcerative colitis

Indexed keywords

ADENOSINE DEAMINASE; C REACTIVE PROTEIN; DNA; HEMOGLOBIN;

ADENOSINE DEAMINASE BLOOD LEVEL; ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; LEUKOCYTE; MALE; PRIORITY JOURNAL; REMISSION; SENSITIVITY AND SPECIFICITY; SERUM; ULCERATIVE COLITIS;

ADENOSINE DEAMINASE; ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84855939304     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.010     Document Type: Article

References (43)

1. Kucharzik T., Maaser C., Lügering A., Kagnoff M., Mayer L., Targan S., Domschke W. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm Bowel Dis 2006, 12:1068-1083.
2. Thoreson R., Cullen J.J. Pathophysiology of inflammatory bowel disease: an overview. Surg Clin North Am 2007, 87:575-585.
3. Yüksel O., Helvaci K., Başar O., Köklü S., Caner S., Helvaci N., Abayli E., Altiparmak E. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009, 20:277-281.
4. Solberg I.C., Lygren I., Jahnsen J., Aadland E., Høie O., Cvancarova M., Bernklev T., Henriksen M., Sauar J., Vatn M.H., Moum B. Clinical course during the first 10years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009, 44:431-440. IBSEN Study Group.
5. Caprilli R., Viscido A., Latella G. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2007, 4:92-101.
6. Sandborn W.J., Loftus E.V., Colombel J.F., Fleming K.A., Seibold F., Homburger H.A., Sendid B., Chapman R.W., Tremaine W.J., Kaul D.K., Wallace J., Harmsen W.S., Zinsmeister A.R., Targan S.R. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2001, 7:192-201.
7. Vermeire S., Van Assche G., Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 2006, 55:426-431.
8. Fox I.H., Kelley W.N. The role of adenosine and 2'-deoxyadenosine in mammalian cells. Annu Rev Biochem 1978, 47:655-686.
9. Sullivan J.L., Osborne W.R., Wedgewood R.J. Adenosine deaminase activity in lymphocytes. Br J Haematol 1977, 37:157-158.
10. Van der Weyden M.B., Kelley W.N. Human adenosine deaminase. Distribution and properties. J Biol Chem 1976, 251:5448-5456.
11. Adams A., Harkness R.A. Adenosine deaminase activity in thymus and other human tissues. Clin Exp Immunol 1976, 26:647-649.
12. Piras M.A., Gakis C., Budroni M., Andreoni G. Adenosine deaminase activity in pleural effusions: an aid to differential diagnosis. Br Med J 1978, 2:1751-1752.
13. Tripathi K., Kumar R., Bharti K., Kumar P., Shrivastav R., Sundar S., Pai K. Adenosine deaminase activity in sera of patients with visceral leishmaniasis in India. Clin Chim Acta 2008, 388:135-138.
14. Erer B., Yilmaz G., Yilmaz F.M., Koklu S. Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy. Rheumatol Int 2009, 29:651-654.
15. Oztürk Z.A., Köklü S., Erol M.F., Yilmaz F.M., Basar O., Yüksel O., Yilmaz G., Kisacik B., Yüksel I. Serum adenosine deaminase levels in diagnosis of acute appendicitis. Emerg Med J 2008, 25:583-585.
16. Hitoglou S., Hatzistilianou M., Gougoustamou D., Athanassiadou F., Kotsis A., Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2001, 20:411-416.
17. Cakal B., Beyazit Y., Koklu S., Akbal E., Biyikoglu I., Yilmaz G. Elevated adenosine deaminase levels in celiac disease. J Clin Lab Anal 2010, 24:323-326.
18. Ibiş M., Köklü S., Yilmaz F.M., Başar O., Yilmaz G., Yüksel O., Yildirim E., Oztürk Z.A. Serum adenosine deaminase levels in pancreatic diseases. Pancreatology 2007, 7:526-530.
19. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989, 298:82-86.
20. Giusti G., Galanti B. Adenosine deaminase: colorimetric method. Methods of Enzymatic Analysis 1984, vol. 4:315-323. Verlac Chemie, Weinheim. 3rd ed. H.U. Bergmeyer (Ed.).
21. Cima R.R., Pemberton J.H. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005, 140:300-310.
22. Caprilli R., Viscido A., Latella G. Current management of severe ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2007, 4:92-101.
23. Travis S.P. Review article: the management of mild to severe acute ulcerative colitis. Aliment Pharmacol Ther 2004, 20(Suppl 4):88-92.
24. Bruining D.H., Loftus E.V. Current and future diagnostic approaches: from serologies to imaging. Curr Gastroenterol Rep 2007, 9:489-496.
25. Bitton A., Peppercorn M.A., Antonioli D.A., Niles J.L., Shah S., Bousvaros A., Ransil B., Wild G., Cohen A., Edwardes M.D., Stevens A.C. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
26. Khan K., Schwarzenberg S.J., Sharp H., Greenwood D., Weisdorf-Schindele S. Role of serology and routine laboratory tests in childhood inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:325-329.
27. Karoui S., Laz S., Serghini M., Bibani N., Boubaker J., Filali A. Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis. Dig Dis Sci 2011, 56:1801-1805.
28. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Renzulli P., Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009, 15:1851-1858.
29. Solem C.A., Loftus E.V., Tremaine W.J., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:707-712.
30. Peterson C.G., Sangfelt P., Wagner M., Hansson T., Lettesjö H., Carlson M. Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative colitis. Scand J Clin Lab Invest 2007, 67:810-820.
31. Sutherland A.D., Gearry R.B., Frizelle F.A. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 2008, 51:1283-1291.
32. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008, 103:162-169.
33. Kisacik B., Akdogan A., Yilmaz G., Karadag O., Yilmaz F.M., Koklu S., Yuksel O., Ertenli A.I., Kiraz S. Serum adenosine deaminase activities during acute attacks and attack-free periods of familial Mediterranean fever. Eur J Intern Med 2009, 20:44-47.
34. Barankiewicz J., Cohen A. Evidence for distinct catabolic pathways of adenine ribonucleotides and deoxyribonucleotides in human T lymphoblastoid cells. J Biol Chem 1984, 259:15178-15181.
35. Aldrich M.B., Blackburn M.R., Kellems R.E. The importance of adenosine deaminase for lymphocyte development and function. Biochem Biophys Res Commun 2000, 272:311-315.
36. Martínez-Hernández D., Arenas-Barbero J., Navarro-Gallar F., García-Esteban R., Santos-Sancho J., Gomez-de-Terreros F. Adenosine deaminase in the acquired immunodeficiency syndrome. Clin Chem 1949, 1988:34.
37. Giblett E.R., Anderson J.E., Cohen F., Pollara B., Meuwissen H.J. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 2:1067-1069.
38. Canpolat F., Unver M., Eskioǧlu F., Kösebalaban S., Durmazlar S.P. Serum and erythrocyte adenosine deaminase activities in patients with Behçet's disease. Int J Dermatol 2006, 45:1053-1056.
39. Nishikawa Y., Nakamura M., Fukumoto K., et al. Adenosine deaminase isoenzymes in patients with Graves' disease. Rinsho Byori 1995, 43:1057-1060.
40. Maor I., Rainis T., Lanir A., Lavy A. Adenosine deaminase activity in patients with Crohn's disease: distinction between active and nonactive disease. Eur J Gastroenterol Hepatol 2011, 23:598-602.
41. Zuckerman S.H., Olson J.M., Douglas S.D. Adenosine deaminase activity during in vitro culture of human peripheral blood monocytes and pulmonary alveolar macrophages. Exp Cell Res 1980, 129:281-287.
42. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
43. Monteleone G., Fina D., Caruso R., Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006, 22:361-364.